Anova Enterprises expands AnovaOS™ to boost clinical development
Category: #health  By Pankaj Singh  Date: 2020-09-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Anova Enterprises expands AnovaOS™ to boost clinical development

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies and research sites together to facilitate just-in-time access to investigational drugs wherever patients receive care. It enhances trial access for physicians, sites, patients, and decreases the time and cost of enrolment, recruitment, and study conduct for sponsors.

Sources cite that AnovaOS™ is presently bringing therapies to patients with infectious diseases and cancer across the globe. The expanded platform will support patients with challenging disease including diabetes, Alzheimer’s, heart disease, Parkinson’s, and other rare diseases. 

The platform can integrate 130,000 active clinical studies and 15,000 investigational drugs for 40,000 sites and creates a first-of-kind on-demand research network. The company’s main goal is to boost clinical development with the industry’s first learning system.

Evidently, the biopharmaceutical sector is facing several challenges clinical during drug development such as rising R&D development, extending timelines, less ROI on R&D investment, surging trial complexity, burgeoning regulatory burden, conflicted partners, leading to increased treatment cost that could lead to bankrupt the entire system.

On the other hand, the demand for clinical studies has been increasing in recent years due to unmet medical needs and the advent of cutting-edge technologies. While the conventional model has effectively developed several important products, the sector is faced with crucial challenges that need cutting-edge solutions like AnovaOSTM. The platform enables patients to access the best treatment, at the correct time, where they want to receive care.

Speaking on the platform, Nassir Habboudi, M.D., CMO of Celularity, Inc. stated that Anova’s approach to expanded access has efficiently brought Celularity investigational therapies to COVID-19 and cancer patients in need while creating data that has impacted the company’s traditional development efforts.

Source Credit - https://www.businesswire.com/news/home/20200916005415/en/Anova-Expands-Technology-Platform-Providing-Patients-With-Access-to-Any-Clinical-Trial-or-Promising-Treatment-Wherever-They-Receive-Care



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

AstraZeneca bags CHMP’s recommendation for Trixeo Aerosphere & Forxiga
AstraZeneca bags CHMP’s recommendation for Trixeo Aerosphere & Forxiga
By Pankaj Singh

 

  • AstraZeneca is likely to get approval from the EU after receiving a recommendation from CHMP
  • AstraZeneca is also cleared to resume i...

Tata Consumer possibly looking to join hands with CCD’s retail outlets
Tata Consumer possibly looking to join hands with CCD’s retail outlets
By Pankaj Singh

TCPL (Tata Consumer Products) is apparently on the lookout for signing a partnership deal with Cafe Coffee Day’s retail outlets. The thought possibly takes shape on the back of the fact that the deal may offer sy...

NuVera announces positive data from FIH feasibility study at TCT meet
NuVera announces positive data from FIH feasibility study at TCT meet
By Pankaj Singh

NuVera Medical Inc., a privately held firm focused on developing novel imaging platform for complex cardiovascular procedures, has reportedly presented positive outcomes from its FIH (First-in-human) feasibility study ...